MAPK3 and non-small cell lung carcinoma: After treatment with ERK1/2 selective inhibitor (U0126), the proliferation and motility of those cells were decreased, supporting that ILT4 induces cancer cell malignant phenotype in NSCLC by activating ERK signaling pathway.